Trial record 1 of 4 for:
atara | PTLD
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03392142 |
|
Recruitment Status :
Completed
First Posted : January 5, 2018
Last Update Posted : March 26, 2021
|
Sponsor:
Atara Biotherapeutics
Information provided by (Responsible Party):
Atara Biotherapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Stem Cell Transplant Complications Lymphoproliferative Disorders | Biological: tabelecleucel | Phase 3 |
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV+ PTLD in the setting of allogeneic HCT after failure of rituximab.
Tabelecleucel will be selected for the subject from the bank of available tabelecleucel cell products based on matching >= 2 human leukocyte antigen (HLA) alleles, at least one of which is a restricting HLA allele, shared between the tabelecleucel donor and the subject's EBV+ PTLD. Sites will provide high resolution subject and subject's graft donor HLA typing results and other information as required by the protocol.
Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2×10^6 cells/kg on Days 1, 8, and 15, followed by observation through Day 35.
NOTE, 29 April 2020: Study sites/locations with status "completed" may be screening EBV+ PTLD HCT subjects in clinical study ATA129-EBV-302 (NCT03394365).
NOTE, 16 February 2021: all study sites have closed and all data has been transferred to the clinical study database for monitoring under ATA129-EBV-302 (NCT03394365).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 8 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab |
| Actual Study Start Date : | December 29, 2017 |
| Actual Primary Completion Date : | February 16, 2021 |
| Actual Study Completion Date : | February 16, 2021 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Herpesvirus 4, Human
| Arm | Intervention/treatment |
|---|---|
|
Experimental: tabelecleucel
Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2 x 10^6 cells/kg on Days 1, 8 and 15, followed by observation through Day 35. Treatment will continue until maximal response, unacceptable toxicity, initiation of non-protocol therapy, or failure of multiple tabelecleucel cell products.
|
Biological: tabelecleucel
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Other Names:
|
Primary Outcome Measures :
- Objective response rate (ORR) [ Time Frame: 2 years ]
Secondary Outcome Measures :
- Overall survival (OS) [ Time Frame: 5 years ]
- Duration of response (DOR) [ Time Frame: 2 years ]
- PTLD progression-free survival (PFS) following best response [ Time Frame: 2 years ]
- Rate of durable response [ Time Frame: 2 years ]
- Time to progression [ Time Frame: 2 years ]
- Patient reported outcome: EQ-5D [ Time Frame: 2 years ]
- Patient reported outcome: Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) [ Time Frame: 2 years ]
- Incidence of related and unrelated adverse events (AE), including AEs of special interest [ Time Frame: 2 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Prior allogeneic hematopoietic cell transplant
- A diagnosis of locally-assessed, biopsy-proven EBV+ PTLD with a pathology sample available for central review
- Availability of appropriate partially HLA-matched and restricted tabelecleucel cell product
- Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score >= 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable quality to the central radiology laboratory prior to Cycle 1 Day 1.
- Failure of rituximab for first-line treatment of PTLD. Note: Subjects with CD20 negative disease are eligible to enroll without prior anti-CD20 therapy after failure of first-line treatment (reduction of immunosuppression is not considered first-line therapy) and discussion with the sponsor's medical monitor.
- Males and females of any age
- Eastern Cooperative Oncology Group (ECOG) performance status <= 3 for subjects aged > 16 years; Lansky score >= 20 for subjects from birth to 16 years
- Underlying primary disease, for which the subject underwent transplant, is in morphologic remission
-
Adequate organ function
- Absolute neutrophil count >= 500/µL, with or without cytokine support
- Platelet count >= 50,000/µL, with or without transfusion support; platelet count < 50,000/µL but >= 20,000/µL, with or without transfusion support, is permissible if the subject has not had Grade >= 2 bleeding in the prior 6 months (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version 5.0)
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3 x the upper limit of normal (ULN); however, ALT, AST, and TBILI each <= 5 x ULN is acceptable if the elevation is considered by the investigator to be due to PTLD involvement of the liver
- Creatinine < 3 x ULN
- Subject or subject's representative is willing and able to provide written informed consent
Exclusion Criteria:
- Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, methotrexate, or extracorporeal photopheresis
- History of central nervous system (CNS) PTLD
- Grade >= 2 graft-versus-host disease (GvHD) per the Center for International Blood and Marrow Transplant Research (CIBMTR) consensus grading system at enrollment
- Ongoing or recent use of a checkpoint inhibitor (eg, nivolumab, pembrolizumab, ipilimumab) within three drug half-lives from the most recent dose to Cycle 1 Day 1
- Active adenovirus viremia
- Need for vasopressor or ventilatory support
- Antithymocyte globulin or similar anti-T cell antibody therapy <= 4 weeks prior to Cycle 1 Day 1
- Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI) within 8 weeks of Cycle 1 Day 1
- Pregnancy
- Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception
- Inability to comply with study-related procedures
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03392142
Locations
Show 27 study locations
Sponsors and Collaborators
Atara Biotherapeutics
Investigators
| Study Director: | Willis Navarro, MD | Atara Biotherapeutics |
| Responsible Party: | Atara Biotherapeutics |
| ClinicalTrials.gov Identifier: | NCT03392142 |
| Other Study ID Numbers: |
ATA129-EBV-301 |
| First Posted: | January 5, 2018 Key Record Dates |
| Last Update Posted: | March 26, 2021 |
| Last Verified: | March 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Atara Biotherapeutics:
|
Epstein-Barr Virus (EBV)-associated Lymphoproliferative Disease (LPD) Hematopoietic Cell Transplantation (HCT) Hematopoietic Stem Cell Transplantation (HSCT) Allogeneic Hematopoietic Cell Transplant Bone Marrow Transplant Complications Cancer After Transplant |
Cytotoxic T lymphocyte (CTL) Epstein-Barr Virus-specific Cytotoxic T Lymphocytes (EBV-CTL) Allogeneic, Off-The-Shelf T-cell Immunotherapy Post-transplant Lymphoma Epstein-Barr Virus (EBV) |
Additional relevant MeSH terms:
|
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |